Molgora et al. found that constitutive lack of TREM2 or anti-TREM2 mAb significantly curbed the growth of tumors and led to complete tumor regression when associated with suboptimal PD-1 immunotherapy (73), the encouraging results indicate that therapeutic strategies targeting TREM2 could keep pace with ICIs in cancer immunotherapy. This evidence concerns the gene TREM2 and neoplasm.